Try our beta test site
45 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) | Depsipeptide
Show Display Options
Rank Status Study
1 Completed A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Lymphoma
Condition: Histologically Proven Extranodal NKTcell Lymphoma
Intervention: Drug: Romidepsin
2 Active, not recruiting
Has Results
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Romidepsin
3 Active, not recruiting Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Romidepsin, Gemcitabine
4 Completed FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Lymphoma
Intervention: Drug: romidepsin
5 Completed Long-term Use of Romidepsin in Patients With CTCL
Condition: Cutaneous T-cell Lymphoma
Intervention: Drug: Romidepsin
6 Completed Depsipeptide in Treating Patients With Solid Tumors
Condition: Lymphoma
Intervention: Drug: romidepsin
7 Completed
Has Results
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
Condition: Cutaneous T-cell Lymphoma
Intervention: Drug: romidepsin (depsipeptide, FK228)
8 Recruiting Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
Conditions: Lymphoma;   T-Cell Lymphoma;   Cutaneous Lymphoma
Interventions: Drug: Istodax;   Drug: Doxil
9 Recruiting Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Conditions: Lymphoma;   Relapsed/Refractory T-cell Lymphomas
Interventions: Drug: Romidepsin;   Drug: Bortezomib;   Drug: duvelisib
10 Unknown  A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.
Condition: Peripheral T Cell Lymphoma (PTCL)
Intervention: Drug: Depsipeptide
11 Active, not recruiting
Has Results
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
Condition: Lymphoma, T-cell, Peripheral
Intervention: Drug: Romidepsin
12 Active, not recruiting
Has Results
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Conditions: Cutaneous T Cell Lymphoma;   Peripheral T Cell Lymphoma
Intervention: Drug: Romidepsin
13 Recruiting Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Romidepsin + CHOP;   Drug: CHOP
14 Active, not recruiting Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Romidepsin;   Drug: Ifosfamide;   Drug: Mesna;   Drug: Carboplatin;   Drug: Etoposide
15 Active, not recruiting Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Conditions: T-cell Lymphomas;   Relapsed or Refractory
Interventions: Drug: Carfilzomib;   Drug: Romidepsin;   Drug: Lenalidomide
16 Terminated
Has Results
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Intervention: Drug: romidepsin
17 Terminated FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
Conditions: Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Small Lymphocytic Lymphoma
Interventions: Drug: romidepsin;   Biological: rituximab;   Drug: fludarabine phosphate;   Other: laboratory biomarker analysis
18 Completed A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas
Condition: Peripheral T Cell Lymphoma
Intervention: Drug: Romidepsin and CHOP
19 Not yet recruiting A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
Condition: Cutaneous T-cell Lymphoma (CTCL)
Interventions: Drug: Romidepsin;   Drug: Brentuximab vedotin
20 Recruiting Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Romidepsin;   Drug: Poly ICLC;   Radiation: Focal lesional radiation

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.